              
              Spanish Version
            
                    search
                    close

Johnson & Johnson selects Peru for COVID-19 vaccine trials

Laboratories are working against the clock to produce a vaccine against COVID-19. Photo: ANDINA/Difusión

00:55 | Lima, Aug. 25.

The Ministry of Foreign Affairs has reported that Johnson & Johnson selected Peru to participate in phase 3 of the clinical study for its candidate vaccine against COVID-19.

On Monday, Johnson & Johnson and its pharmaceutical group Janssen confirmed that Peru will be one of the countries chosen for the phase 3 clinical study, in which the effectiveness of a candidate vaccine to prevent the COVID-19 will be evaluated.

For more than a month, Johnson & Johnson has been evaluating potential venues for its trial, considering criteria such as the epidemiological profiles of countries, the conditions of their research infrastructure and the regulatory approval process.

By engaging in coordination with the company, Peru complied with the established requirements, proving its commitment to contributing to a solution to the pandemic.

Currently, phase 2 of the Johnson & Johnson clinical study is in progress in the United States and Belgium. The results of this stage are expected to be available in September, after which phase 3 may begin.

For its part, phase 3 will summon 60,000 volunteers aged between 18 and 60 from around the world.

The participation of Peruvian citizens will make it possible to contribute to international efforts aimed at developing a safe and effective vaccine against COVID-19 that allows controlling the spread of the SARS-CoV-2 virus and reactivating global economies.

It should be mentioned that the selection of Peru for this clinical study is part of the announcement made by the President of the Republic Martin Vizcarra and was achieved thanks to his leadership and the coordinated work of the Ministry of Health, the National Health Institute, the Embassy of Peru in the United States and the Ministry of Foreign Affairs.

(END) NDP/RMCH/MVB

Published: 8/24/2020

Video más visto

Johnson & Johnson selects Peru for COVID-19 vaccine trials

Most read